EPA Compositions for Lowering hs-CRP in Cardiovascular Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases and disorders, particularly those characterized by elevated high-sensitivity C-reactive protein (hs-CRP) levels, are inadequate in effectively lowering hs-CRP and managing associated conditions such as high blood pressure and dyslipidemia.
Innovation Solution
Administration of pharmaceutical compositions comprising eicosapentaenoic acid (EPA) or its derivatives, such as ethyl eicosapentaenoate, to subjects with elevated hs-CRP levels, either alone or in conjunction with statin therapy, to reduce hs-CRP levels and treat cardiovascular-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cardiovascular diseases, then patients receive standard therapy, but hs-CRP levels remain elevated and inflammatory conditions are not effectively managed
Solution Approach 1:
The patent introduces a novel parameter (EPA dosage ranging from 1g to 4g per day) to change the therapeutic approach. By administering specific doses of eicosapentaenoic acid, the treatment effectively lowers hs-CRP levels by 5-25%, resolving the contradiction between standard therapy reliability and the harmful effect of elevated inflammatory markers.
2Object-affected harmful factors
If EPA compositions are administered to lower hs-CRP levels, then inflammatory markers are reduced, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent demonstrates that EPA compositions serve multiple functions simultaneously: they lower hs-CRP levels by 5-25%, reduce triglycerides, improve lipid profiles, and can be used with or without statin therapy. This multi-functionality simplifies the overall treatment approach by addressing multiple cardiovascular risk factors with a single intervention.
3Object-affected harmful factors
If high doses of EPA are administered to achieve significant hs-CRP reduction, then anti-inflammatory effects are enhanced, but the quantity of substance required increases
Solution Approach 1:
The patent employs partial action by administering EPA doses ranging from 1g to 4g per day, which is sufficient to achieve the therapeutic goal of lowering hs-CRP levels by 5-25%. This optimized dosage range avoids excessive administration while maintaining effective anti-inflammatory and cardiovascular protective effects.
Data Source
AI summary
The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In some embodiments, the method comprises lowering high sensitivity CRP (hs-CRP) levels in a subject including, for example, a subject with a HbA1c value of about 5.00%-8.50% or at least about 6.8%.